7 547

Cited 9 times in

Current status of Parkinson's disease treatment in Korea

Authors
 Jin-Soo Kim  ;  Young H Sohn 
Citation
 PARKINSONISM & RELATED DISORDERS, Vol.9(Suppl.2) : 99-104, 2003 
Journal Title
 PARKINSONISM & RELATED DISORDERS 
ISSN
 1353-8020 
Issue Date
2003
MeSH
Alzheimer Disease/epidemiology ; Antiparkinson Agents/supply & distribution ; Antiparkinson Agents/therapeutic use ; Humans ; Incidence ; Korea/epidemiology ; National Health Programs/statistics & numerical data* ; Parkinson Disease/drug therapy ; Parkinson Disease/epidemiology* ; Prevalence
Keywords
Parkinson's disease ; Korea ; Health insurance ; Epidemiology
Abstract
The health insurance system in Korea has been under governmental control, and has covered whole population since 1989. About 97% of Korean people have benefits from this system, while 3% are covered by a Medical Aid system for poor people. According to the statistical yearbook of Health Insurance Review in Korea, the number of claims under Parkinson's Disease, in whole country increased steeply from 44619 in 1995 to 96229 in 2000. If each patient were to take medication for the full duration of their insurance coverage, the average number of visits per year would be 11 in 2000. Thus the number of PD patients calculated using these statistics is about 8600. The prevalence is 19/100000, which is much lower than that in Japan. Considering the significant increase in the number of claims in last few years, however, there are still many PD patients who do not receive an accurate diagnosis and appropriate treatment. The other factor influencing these statistics is the fact that patients were able to buy their medications in drug stores without prescription, i.e. without visiting a hospital (since 2001 this has no longer been allowed). Almost all PD medications are available in Korea. There are several forms of levodopa drugs. Dopamine agonists include bromocriptine, pergolide, dihydroergocriptine, ropinirol, and pramipexole. Other parkinsonian medications are amantadine, benztropin, trihexyphenydil, deprenyl, and entacapone. Recently multicentre clinical trials were performed using ropinirol and entacapone, which showed reliable results. Currently deep brain stimulation is available in a number of medical institutes.
Full Text
http://www.sciencedirect.com/science/article/pii/S1353802003000257
DOI
10.1016/S1353-8020(03)00025-7
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Neurology (신경과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jin Soo(김진수)
Sohn, Young Ho(손영호) ORCID logo https://orcid.org/0000-0001-6533-2610
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/114701
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse